Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat. Participants received a combination of two drugs: (1) recombinant human growth hormone (or its placebo) and (2) pioglitazone (or its placebo). We measured the abdominal fat content and blood sugar levels of participants before and after 40 weeks of treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Stanford University
• Treatments: Hormones; Pioglitazone

Criteria

Inclusion Criteria:

• Age between 40 and 75 years

• BMI > 27 kg/m2

• Waist circumference >100 cm for men and > 88 cm for women

• Impaired glucose tolerance (documented by a 75 gram OGTT)

Exclusion Criteria:

• Diabetes mellitus

• Malignancy

• Premenopausal women who are breastfeeding or decline contraception

• Congestive heart failure

• ALT > 3 times upper normal limit